These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29473145)

  • 1. Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.
    Schuck RN; Woodcock J; Zineh I; Stein P; Jarow J; Temple R; Permutt T; LaVange L; Beaver JA; Charlab R; Blumenthal GM; Dorff SE; Leptak C; Lemery S; Rogers H; Chowdhury B; Litwack ED; Pacanowski M
    Clin Pharmacol Ther; 2018 Aug; 104(2):282-289. PubMed ID: 29473145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
    Do K; O'Sullivan Coyne G; Chen AP
    Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-biomarker co-development in oncology - 20 years and counting.
    Twomey JD; Brahme NN; Zhang B
    Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
    Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Stevens H; Gilbert H; Risser P; Kalamegham R; Jordan J; Engel J; Chen S; Essioux L; Williams JA
    Clin Transl Sci; 2017 Mar; 10(2):84-92. PubMed ID: 28121072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
    Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
    Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 9. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
    Kadia TM; Ravandi F; Cortes J; Kantarjian H
    JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy: a potential oversight in trial protocol.
    Moorthy T
    Lancet Oncol; 2018 Sep; 19(9):e439. PubMed ID: 30191846
    [No Abstract]   [Full Text] [Related]  

  • 11. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.
    Ocana A; Ethier JL; Díez-González L; Corrales-Sánchez V; Srikanthan A; Gascón-Escribano MJ; Templeton AJ; Vera-Badillo F; Seruga B; Niraula S; Pandiella A; Amir E
    Oncotarget; 2015 Nov; 6(37):39538-49. PubMed ID: 26446908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.
    Berry DA; Herbst RS; Rubin EH
    Clin Cancer Res; 2012 Feb; 18(3):638-44. PubMed ID: 22298897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
    Tsimberidou AM
    Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging Genomic Factors to Improve Benefit-Risk.
    Schuck RN; Charlab R; Blumenthal GM
    Clin Transl Sci; 2017 Mar; 10(2):78-83. PubMed ID: 28160443
    [No Abstract]   [Full Text] [Related]  

  • 17. Systems Pharmacology-Based Discovery of Natural Products for Precision Oncology Through Targeting Cancer Mutated Genes.
    Fang J; Cai C; Wang Q; Lin P; Zhao Z; Cheng F
    CPT Pharmacometrics Syst Pharmacol; 2017 Mar; 6(3):177-187. PubMed ID: 28294568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New ESMO scale ranks mutations as cancer medicine targets.
    Fricker J
    Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495
    [No Abstract]   [Full Text] [Related]  

  • 19. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
    Coyne GO; Takebe N; Chen AP
    Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.